0000950142-17-001786.txt : 20171003
0000950142-17-001786.hdr.sgml : 20171003
20171003173428
ACCESSION NUMBER: 0000950142-17-001786
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171003
FILED AS OF DATE: 20171003
DATE AS OF CHANGE: 20171003
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hargadon Robert Bernard
CENTRAL INDEX KEY: 0001381471
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-16789
FILM NUMBER: 171119393
MAIL ADDRESS:
STREET 1: 4327 LAKE WASHINGTON BLVD NE #6208
CITY: KIRKLAND
STATE: WA
ZIP: 98033
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ALERE INC.
CENTRAL INDEX KEY: 0001145460
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 043565120
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 51 SAWYER ROAD
STREET 2: SUITE 200
CITY: WALTHAM
STATE: MA
ZIP: 02453
BUSINESS PHONE: 7816473900
MAIL ADDRESS:
STREET 1: 51 SAWYER ROAD
STREET 2: SUITE 200
CITY: WALTHAM
STATE: MA
ZIP: 02453
FORMER COMPANY:
FORMER CONFORMED NAME: INVERNESS MEDICAL INNOVATIONS INC
DATE OF NAME CHANGE: 20010720
4
1
es1701010_4-hargadon.xml
OWNERSHIP DOCUMENT
X0306
4
2017-10-03
1
0001145460
ALERE INC.
ALR
0001381471
Hargadon Robert Bernard
51 SAWYER ROAD
SUITE 200
WALTHAM
MA
02453
0
1
0
0
SVP, Global Human Resources
Common Stock
2017-10-03
4
D
0
26190
D
0
D
Employee Stock Option (Right to Buy)
29.55
2017-10-03
4
D
0
20000
D
Common Stock
20000
0
D
Employee Stock Option (Right to Buy)
26.06
2017-10-03
4
D
0
5000
D
Common Stock
5000
0
D
Employee Stock Option (Right to Buy)
45.47
2017-10-03
4
D
0
35000
D
Common Stock
35000
0
D
Employee Stock Option (Right to Buy)
25.43
2017-10-03
4
D
0
800
D
Common Stock
800
0
D
Employee Stock Option (Right to Buy)
25.68
2017-10-03
4
D
0
9600
D
Common Stock
9600
0
D
Employee Stock Option (Right to Buy)
36.74
2017-10-03
4
D
0
1250
D
Common Stock
1250
0
D
Restricted Stock Units
2017-10-03
4
D
0
16324
D
Common Stock
16324
0
D
Pursuant to that certain Agreement and Plan of Merger, dated as of January 30, 2016, as amended on April 13, 2017 (the "Merger Agreement"), between Alere Inc. (the "Company") and Abbott Laboratories, at the Effective Time (as defined in the Merger Agreement) (the "Effective Time"), each of these shares of the Company's common stock (the "Common Stock") was converted into the right to receive $51.00 (the "Merger Consideration").
Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.
Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, at the Effective Time, each outstanding Restricted Stock Unit was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time and (ii) the Merger Consideration.
/s/ Doug Barry, Attorney-in-Fact
2017-10-03